Skip to main content

Table 5 List of SHPT medication changes before and after the study

From: Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial

   Dose of cinacalcet hydrochloride before switching
SHPT-related agent Time 25 mg 50 mg ≥ 75 mg Total
Active vitamin D agent SCR 48 (90.6) 18 (100.0) 17 (89.5) 83 (92.2)
24 weeks 50 (94.3) 17 (94.4) 18 (94.7) 85 (94.4)
Ca-based phosphate binder SCR 30 (56.6) 9 (50.0) 7 (36.8) 46 (51.1)
24 weeks 33 (62.3) 9 (50.0) 6 (31.6) 48 (53.3)
Lanthanum carbonate SCR 37 (69.8) 14 (77.8) 15 (78.9) 66 (73.3)
24 Weeks 34 (64.2) 14 (77.8) 13 (68.4) 61 (67.8)
Sevelamer SCR 14 (26.4) 8 (44.4) 7 (36.8) 29 (32.2)
24 weeks 12 (22.6) 7 (38.9) 7 (36.8) 26 (28.9)
Iron-based phosphate binder SCR 14 (26.4) 2 (11.1) 7 (36.8) 23 (25.6)
24 weeks 12 (22.6) 2 (11.1) 6 (31.6) 20 (22.2)
Bixalomer SCR 6 (11.3) 1 ( 5.6) 1 ( 5.3) 8 ( 8.9)
24 weeks 5 ( 9.4) 1 ( 5.6) 1 ( 5.3) 7 ( 7.8)
  1. SHPT secondary hyperparathyroidism, SCR screening